ArticleThe Journal of antimicrobial chemotherapy2022
Resistance mechanisms and molecular epidemiology of Pseudomonas aeruginosa strains from patients with bronchiectasis.
Article in The Journal of antimicrobial chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Rapid and visually interpretable LAMP assay for detection of pathogenic Pseudomonas aeruginosa in artificial sputum.Molecular biology reports · 2026Article
- Epidemiological insights into Haemophilus influenzae and Pseudomonas aeruginosa persistent colonization in non-cystic fibrosis bronchiectasis patients: a longitudinal and multicenter study.Respiratory research · 2026Article
- Antimicrobial Resistance Mechanisms in Carbapenem-ResistantPolish journal of microbiology · 2025Article
- Unveiling the molecular epidemiology of Pseudomonas aeruginosa in lung infections among cystic fibrosis patients in the Brazilian Amazon.BMC microbiology · 2025Article
- Antibiotic Resistance and Virulence Determinants ofMicroorganisms · 2025Article
- Virulence factors of Pseudomonas aeruginosa and immune response during exacerbations and stable phase in bronchiectasis.Scientific reports · 2025Article
- Article
- Fluoroquinolone resistance in ESKAPE pathogens: evolutionary pathways, one health transmission, and clinical surveillance.Frontiers in microbiology · 2025Review
- TIRESIA and TISBE: Explainable Artificial Intelligence Based Web Platforms for the Transparent Assessment of the Developmental Toxicity of Chemicals and Drugs.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer AgainstAntibiotics (Basel, Switzerland) · 2024Article
- Molecular Epidemiology ofAntibiotics (Basel, Switzerland) · 2024Review
- Identification ofVeterinary world · 2024Article
- Quorum-sensing regulation of phenazine production heightensAntimicrobial agents and chemotherapy · 2024Article
- Rapid, sensitive, and user-friendly detection of Pseudomonas aeruginosa using the RPA/CRISPR/Cas12a system.BMC infectious diseases · 2024Article
- In Silico Molecular Analysis of Carbapenemase-Negative Carbapenem-ResistantMicroorganisms · 2024Article
- Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy.Pharmaceutics · 2023Article
- Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Isolation ofMolecules (Basel, Switzerland) · 2023Article
- The value of biofilm testing to guide antimicrobial stewardship in chronic respiratory diseases.Frontiers in cellular and infection microbiology · 2023Article
- Evaluation and analysis of multidrug resistance- and hypervirulence-associated genes in carbapenem-resistantFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundNon-cystic fibrosis bronchiectasis (BE) is a chronic structural lung condition that facilitates chronic colonization by different microorganisms and courses with recurrent respiratory infections and frequent exacerbations. One of the main pathogens involved in BE is Pseudomonas aeruginosa.
objectivesTo determine the molecular mechanisms of resistance and the molecular epidemiology of P. aeruginosa strains isolated from patients with BE.
methodsA total of 43 strains of P. aeruginosa were isolated from the sputum of BE patients. Susceptibility to the following antimicrobials was analysed: ciprofloxacin, meropenem, imipenem, amikacin, tobramycin, aztreonam, piperacillin/tazobactam, ceftazidime, ceftazidime/avibactam, ceftolozane/tazobactam, cefepime and colistin. The resistance mechanisms present in each strain were assessed by PCR, sequencing and quantitative RT-PCR. Molecular epidemiology was determined by MLST. Phylogenetic analysis was carried out using the eBURST algorithm.
resultsHigh levels of resistance to ciprofloxacin (44.19%) were found. Mutations in the gyrA, gyrB, parC and parE genes were detected in ciprofloxacin-resistant P. aeruginosa strains. The number of mutated QRDR genes was related to increased MIC. Different β-lactamases were detected: blaOXA50, blaGES-2, blaIMI-2 and blaGIM-1. The aac(3)-Ia, aac(3)-Ic, aac(6″)-Ib and ant(2″)-Ia genes were associated with aminoglycoside-resistant strains. The gene expression analysis showed overproduction of the MexAB-OprM efflux system (46.5%) over the other efflux system. The most frequently detected clones were ST619, ST676, ST532 and ST109.
conclusionsResistance to first-line antimicrobials recommended in BE guidelines could threaten the treatment of BE and the eradication of P. aeruginosa, contributing to chronic infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.